B-ALL
Conditions
Brief summary
This is an open label, phase I study to assess the safety, efficacy and pharmacokinetics of ThisCART19A in patients with MRD+ B-ALL
Interventions
BIOLOGICALThisCART19A
ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
Sponsors
Zhejiang University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Inclusion Criteria: 1. All subjects or legal representatives must sign a voluntary letter of consent approved by the IRB in person prior to the commencement of any screening procedure; 2. Patients diagnosed with B-ALL according to the Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Lymphoblastic Leukemia (2021 edition); 3. There is no gender limitation, age 18-65 (upper limit not included); 4. Disease status ≥CR2 with bone marrow flow cytometry MRD≥0.1%. 5. Patients with Ph+ R/R ALL who failed after 2-line TKI treatment, were intolerant to TKI treatment or were not suitable for TKI treatment; 6. The expected survival time is ≥12 weeks; 7. ECOG score 0-1; 8. Had good organic function during screening 9. CD19 was still expressed on leukemia cells in bone marrow, peripheral blood or biopsy tissue by flow cytometry, results within one month prior to informed consent are acceptable (after the last treatment).
Exclusion criteria
1. Allergic to preconditioning measures. 2. Patients with other malignancies other than B-cell malignancies within 5 years prior to screening. Patients with cured skin squamous carcinoma,basal carcinoma, non-primary invasive bladder cancer, localized low-risk prostate cancer, in situ cervical/breast cancer can be recruited. 3. Uncontrollable bacterial, fungal and viral infection during screening. 4. Patients had pulmonary embolism within 3 months prior to enrollment. 5. Had intolerant severe cardiovascular and cerebrovascular diseases and hereditary diseases prior to enrollment. 6. Imaging confirmed the presence of central nervous system involvement (both primary and secondary) and obvious symptoms at the time of screening. 7. \< 100 days after hematopoietic stem cell transplantation. 8. Active HBV or HCV or HIV or Syphilis infection. HBV-DNA \< 2000 IU/mL can be enrolled, but should admitted to use anti-virus drugs such as entecavir, tenufovir, etc, and supervisory the relative indication during the treatment. 9. Combined systemic steroid use (e.g., prednisone ≥20mg) within 3 days prior to screening. Or systemic diseases that require long-term use of immunization Inhibitor. 10. Vaccinated with influenza vaccine within 2 weeks prior to cleansing (SARS-COV19 can be included, inactivated, live/non-live adjuvant vaccinations allowed to be included) . 11. Patients who are receiving GvHD treatment; Patients without GvHD and who had stopped immunosuppressive drugs for at least 1 month were eligible for inclusion. 12. Women who are in pregnant or lactating, and female subjects or partners who plan to be pregnant within 1 year after cell infusion. Male subjects who plan pregnancy within 1 year after infusion. 13. Any ineligibility conditions considered by the investigator that may increase the risk of the subject or interfere with the results of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-limiting toxicity (DLT) | Up to 28 days after ThisCART19A infusion | DLT is defined as the incidence of severe adverse events related to ThisCART19A more than 33% in each dose level. |
| The incidence of all grade TEAEs and ≥3 grade TEAEs | Up to 2 years after ThisCART19A infusion | Incidence of treatment-emergent adverse events (TEAEs) and ≥3 grade TEAEs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The change characteristics of chimeric antigen receptor(CAR)-T cell number and copy number in patients after infusion | 3 months | Track CAR-T cells expansion in patients after infusion by flow cytometry and qPCR |
| Relapse-Free Survival | 24 months | Defined as the time from the infusion of ThisCART19A cells to the occurrence of hematologic relapse or death from any cause.Hematologic recurrence was defined as ≥5% of bone marrow lymphoblasts or extramedullary recurrence after CR or CRi |
| Changes in immune effect cells count after ThisCART19A infusion. | 3 months | Calculate the change of immune effect cells count in peripheral blood by flow cytometry after ThisCART19A infusion. Immune effect cells include T cell, B cell, NK cell. |
| Changes in cytokine level after ThisCART19A infusion. | 3 months | Calculate the change of cytokine level in peripheral blood by flow cytometry after ThisCART19A infusion. Cytokines include IL-1β、IL-2、IL-4、IL-6、IL-8、IL-10、IL-12、IL-17、TNF-α、IFN-γ、TGF-β. |
| MRD response rate | At Month 1, 2, 3 | Percentage of participants with minimal residual disease (MRD) response in patients with CR (complete response) and CRi (CR with incomplete blood count recovery) ; MRD Response is defined as leukemic cells in bone marrow \<0.01% by flow cytometry (sensitivity at least 0.001%) |
Countries
China
Contacts
Primary ContactMingming z Zhang, Doctor
Outcome results
None listed